Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514696 | 1.00 | NR1H2 (0.62) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL515486 | 1.00 | NR1H2 (0.62) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL344915 | 0.90 | NR1H2 (0.59) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL1785894 | 0.90 | NR1H2 (0.59) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL344916 | 0.90 | NR1H2 (0.59) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL24106626 | 0.90 | NR1H2 (0.66) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL190460 | 0.90 | NR1H2 (0.61) | NR1H2HPGDKDM4EPKMMAPT | |
| SCHEMBL6218596 | 0.90 | NR1H2 (0.61) | NR1H2HPGDKDM4EPKMMAPT | |
| SCHEMBL2071987 | 0.89 | NR1H2 (0.57) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL31421589 | 0.89 | NR1H2 (0.57) | NR1H2HPGDMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1025 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557836-A | Preparation method of carboxylic acid | 云南大学 | 2023-01-03 | — | — | CN | claimed |
| CN-109232350-A | A method of preparing N-Boc-3- pyrrolidine formaldehyde | 辽宁东科药业有限公司 | 2019-01-18 | — | — | CN | claimed |
| CN-105924379-A | Preparation method of 1-BOC-3-hydroxymethyl pyrrolidine | 苏州艾缇克药物化学有限公司 | 2016-09-07 | — | — | CN | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-20260055099-A1 | PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2026-02-26 | — | — | US | disclosed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000031032-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
| EP-0500835-B1 | A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAE WOONG PHARMA (KR) | 1996-12-27 | — | — | EP | disclosed |
| CN-1019114-B | QUINOLINE-3-CARBOXYLIC ACID DERIVATIVES AND THE PREPN. METHOD THEREOF | SANKYO CO (JP) | 1992-11-18 | — | — | CN | disclosed |
| EP-0500835-A1 | A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE. | DAE WOONG PHARMA (KR) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004342-A1 | A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 1992-03-19 | — | — | WO | disclosed |
| US-4997943-A | Bactericides | SANKYO COMPANY LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| CN-87103693-A | Quinoline-3-carboxylic acid derivatives and its preparation and application | — | 1988-03-30 | — | — | CN | disclosed |
| EP-0241206-A2 | Quinoline-3-carboxylic acid derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | NR1H2 2747/4885HPGD 3204/4885KDM4E 4425/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | NR1H2 908/4885HPGD 4101/4885KDM4E 705/4885 |
| US-20260055099-A1 | PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER | KAT2A, KAT2B, KAT8 | NR1H2 87/4885HPGD 4467/4885KDM4E 259/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | NR1H2 92/4885HPGD 1047/4885KDM4E 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.